Furthermore, adenoviral recombinant gene therapy for Trx1 can significantly increase the expression of Trx1 in the myocardium of STZ-induced diabetic rats, decrease disulfide stress and ROS, alleviate myocardial infarction and fibrosis, increase the density of capillaries and small arteries, reduce infarct area, and improve cardiac function [85,86]. Here, TXN is linked to myocardial infarction.